YING-JUI HOCHIH-LI LIN2026-10-162026-10-162018-01-01Pure ID: 15251983Pure UUID: 45a70d1e-4b03-405d-86ea-1549cf26c6a610.1155/2018/4618716https://www.scopus.com/pages/publications/85054991548https://scholars.csmu.edu.tw/handle/123456789/27807Dementia with Lewy bodies (DLB) is characterized by neuronal deficits and α-synuclein inclusions in the brain. Ceftriaxone (CEF), a β-lactam antibiotic, has been suggested as a therapeutic agent in several neurodegenerative disorders for its abilities to counteract glutamate-mediated toxicity and to block α-synuclein polymerization. By using manganese-enhanced magnetic resonance imaging (MEMRI) and immunohistochemistry, we measured the effects of CEF on neuronal activity and α-synuclein accumulation in the brain in a DLB rat model. The data showed that CEF corrected neuronal density and activity in the hippocampal CA1 area, suppressed hyperactivity in the subthalamic nucleus, and reduced α-synuclein accumulation, indicating that CEF is a potential agent in the treatment of DLB.enjournal article